Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

NCT03321968 PHASE3 COMPLETED Results posted

This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine, during the 2016-2017 influenza season, in healthy adults 18-49 years of age. A single dose of one of three consecutive lots of Quadrivalent VLP Influenza Vaccine (30 µg/strain) will be administered to 1,200 participants.

Details

Lead sponsor	Medicago
Phase	PHASE3
Status	COMPLETED
Enrolment	1202
Start date	Fri Sep 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Virus Diseases
• RNA Virus Infections
• Respiratory Tract Infections
• Respiratory Tract Disease
• Influenza

Interventions

• Quadrivalent VLP Influenza Vaccine

Countries

Canada